BLENREP (GlaxoSmithKline Australia Pty Ltd)
Product name
BLENREP
Date registered
Evaluation commenced
Decision date
Approval time
168 (255 working days)
Active ingredients
belantamab mafodotin
Registration type
NCE/NBE
Indication
BLENREP is indicated for the treatment of adults with relapsed or refractory multiple myeloma:
- in combination with bortezomib and dexamethasone in patients who have received at least one prior therapy; and
- in combination with pomalidomide and dexamethasone in patients who have received at least one prior therapy including lenalidomide.